[{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laminar Pharmaceuticals S.A. Receives Recommendation from The Independent Data Monitoring Committee to Advance to the Next Stage of CLINGLIO, the Phase 2b\/3 Clinical Trial of LAM561 in Combination with RT and TMZ for Adults with Newly Diagnosed Glioblasto","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laminar Completes Recruitment for LAM561 in Glioblastoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Laminar Pharma
LAM561 (2-hydroxyoleic acid) is an oral synthetic derivative of oleic. It is being evaluated in combination with TMZ & RT for the treatment of glioblastoma.
LAM561 (2-hydroxyoleic acid (2-OHOA); idroxioleic acid, sodium) is a synthetic derivative of oleic acid and the most advanced R&D product which is taken orally. It is being evaluated in combination with TMZ & RT for the treatment of newly diagnosed glioblastoma.
Lead Product(s):
2-Hydroxyoleic Acid (2-Ohoa); Idroxioleic Acid, Sodium,Temozolomide